Biotechnology - Medivation

Filter

Current filters:

Medivation

Popular Filters

Promising emerging agents for triple negative breast cancer

08-04-2014

Due to the heterogeneity of triple negative breast cancer, the most promising emerging agents in development…

Astellas PharmaBiotechnologyMarkets & MarketingMedivationniraparibOncologyTesaroXtandi

FDA backs Medivation and Astellas' prostate cancer drug Xtandi

03-09-2012

USA-based Medivation (Nasdaq: MDVN and Japanese drug major Astellas Pharma (TYO: 4503) say that the US…

Astellas PharmaBiotechnologyenzalutamideMedivationNorth AmericaOncologyPharmaceuticalRegulationXtandi

Expanded Access Program for enzalutamide agreed with US FDA

30-05-2012

The US Food and Drug Administration agreed that Medivation (Nasdaq: MDVN) and Japanese drug major Astellas…

Astellas PharmaBiotechnologyenzalutamideMDV3100MedivationNorth AmericaOncologyPharmaceuticalRegulation

Emerging therapies will drive prostate cancer drug market to $10.1 billion in 2020

08-11-2011

Driven by the launches of several promising emerging therapies, the prostate cancer drug market will…

Astellas PharmaBiotechnologyGlobalJohnson & JohnsonMarkets & MarketingMedivationOncologyPharmaceuticalZytiga

Parexel

Parexel

Back to top